Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Developing a prognostic model for skin melanoma based on the persistent tumor mutation burden and determining IL17REL as a therapeutic target.

Journal of cancer research and clinical oncology - 20 Jun 2024

Xu Mingze, Ma Xinyi, Wang Yuchong, Yu Ziqin, Zheng Xiaoli, Dai Haiying, Xue Chunyu

Abstract excerpt

BACKGROUND: One popular and well-established marker for the immune checkpoint blockade (ICB) response is tumor mutation burden (TMB). Persistent TMB (pTMB), a subset of TMB, provides a better indicator to predict patient ICB therapy outcomes, as shown by some studies. Immune checkpoint drugs have significantly changed how melanoma is treated in recent years. METHODS: In this study, we integrated the TCGA-SKCM...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Interleukin-17

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Melanoma, Cutaneous Malignant

Share to Mutation

Share to Prognosis

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 38900244
DOI: 10.1007/s00432-024-05843-x
PMCID: PMC11189994

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Developing a prognostic model for skin melanoma based on the persistent tumor mutation burden and determining IL17REL as a therapeutic target.PMID 38900244Read ↗

Identification of Prognostic Biomarkers of Cutaneous Melanoma Based on Analysis of Tumor Mutation Burden.Semantic proximity Read ↗

Multi-omics analysis of tumor mutation burden combined with immune infiltrates in melanoma.Semantic proximity Read ↗

Significance of Tumor Mutation Burden in Immune Infiltration and Prognosis in Cutaneous MelanomaSemantic proximity Read ↗

Genomic landscape of the immunogenicity regulation in skin melanomas with diverse tumor mutation burden.Semantic proximity Read ↗

Gene expression and immune infiltration in melanoma patients with different mutation burden.Semantic proximity Read ↗

The combination of single-cell and bulk RNA sequencing analysis decodes the melanoma tumor microenvironment and identifies novel T cell-associated signature genesSemantic proximity Read ↗

Prognostic Role of Tumor Mutation Burden Combined With Immune Infiltrates in Skin Cutaneous Melanoma Based on Multi-Omics AnalysisSemantic proximity Read ↗

Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.Semantic proximity Read ↗

Molecular Pathology of Skin Melanoma: Epidemiology, Differential Diagnostics, Prognosis and Therapy PredictionSemantic proximity Read ↗

Molecular, Genetic Susceptibility and Immunotherapy of MelanomaSemantic proximity Read ↗

Prognostic Modeling of Patients with Metastatic Melanoma Based on Tumor Immune Microenvironment CharacteristicsSemantic proximity Read ↗

A novel immune-related genes prognosis biomarker for melanoma: associated with tumor microenvironmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.